Education
About Us
Working with TipRanks
Follow Us
Pelthos Therapeutics (PTHS)
:PTHS
Total Valuation
Pelthos Therapeutics has a market cap or net worth of $81.80M. The enterprise value is $74.95M.
Market Cap$81.80M
Enterprise Value$74.95M
Share Statistics
Pelthos Therapeutics has 3,086,681 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,086,681
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Pelthos Therapeutics’s return on equity (ROE) is 2.93 and return on invested capital (ROIC) is 1434.03%.
Return on Equity (ROE)2.93
Return on Assets (ROA)-5.81
Return on Invested Capital (ROIC)1434.03%
Return on Capital Employed (ROCE)2.79
Revenue Per Employee0.00
Profits Per Employee-1.99M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Pelthos Therapeutics is ―. Pelthos Therapeutics’s PEG ratio is -0.15.
PE Ratio―
PS Ratio0.00
PB Ratio-2.55
Price to Fair Value-2.55
Price to FCF-1.20
Price to Operating Cash Flow-4.88
PEG Ratio-0.15
Income Statement
In the last 12 months, Pelthos Therapeutics had revenue of 0.00 and earned -7.96M in profits. Earnings per share was -13.54.
Revenue0.00
Gross Profit0.00
Operating Income-7.57M
Pretax Income-7.96M
Net Income-7.96M
EBITDA-7.17M
Earnings Per Share (EPS)-13.54
Cash Flow
In the last 12 months, operating cash flow was -17.01M and capital expenditures 5.00, giving a free cash flow of -17.01M billion.
Operating Cash Flow-17.01M
Free Cash Flow-17.01M
Free Cash Flow per Share-5.51
Dividends & Yields
Pelthos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.92
52-Week Price Change301.52%
50-Day Moving Average29.44
200-Day Moving Average21.23
Relative Strength Index (RSI)51.80
Average Volume (3m)30.94K
Important Dates
Pelthos Therapeutics upcoming earnings date is Nov 13, 2025, Before Open (Confirmed).
Last Earnings DateAug 18, 2025
Next Earnings DateNov 13, 2025
Ex-Dividend Date―
Financial Position
Pelthos Therapeutics as a current ratio of 0.34, with Debt / Equity ratio of 5.97%
Current Ratio0.34
Quick Ratio0.34
Debt to Market Cap0.32
Net Debt to EBITDA-0.23
Interest Coverage Ratio-9.63
Taxes
In the past 12 months, Pelthos Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Pelthos Therapeutics EV to EBITDA ratio is -1.20, with an EV/FCF ratio of -1.49.
EV to Sales0.00
EV to EBITDA-1.20
EV to Free Cash Flow-1.49
EV to Operating Cash Flow-1.49
Balance Sheet
Pelthos Therapeutics has $14.25M in cash and marketable securities with $3.48M in debt, giving a net cash position of $10.77M billion.
Cash & Marketable Securities$14.25M
Total Debt$3.48M
Net Cash$10.77M
Net Cash Per Share$3.49
Tangible Book Value Per Share-$4.62
Margins
Gross margin is 54.31%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin54.31%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Pelthos Therapeutics is $59.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$59.80
Price Target Upside121.65% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―